



# Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.





## 11q Aberration in NHL

### Alternative Name

11q Gain / Loss

### Methodology

FISH

### Test Description

**Probes:** CEN 11 (11p11.1-q11) | MLL (11q23) | 11qTel (11q25)

**Disease(s):** B-cell non-Hodgkin lymphoma

### Clinical Significance

This FISH panel detects proximal gains and distal losses of chromosome 11q which are recurrent abnormalities in MYC-negative high grade B-cell lymphomas resembling Burkitt lymphoma. "Burkitt-like lymphoma with 11q aberration" was recognized by the WHO in 2017 as a new provisional entity. This pattern of 11q abnormalities is also observed in MYC-positive Burkitt lymphomas and MYC-positive high-grade B-cell lymphomas, not otherwise specified.

### Specimen Requirements

- **Bone Marrow Aspirate:** N/A
- **Peripheral Blood:** N/A
- **Fresh, Unfixed Tissue:** N/A
- **Fluids:** N/A
- **Paraffin Block:** H&E slide (required) plus paraffin block. Circle H&E for tech-only.
- **Cut Slides:** H&E slide (required) plus 2 unstained slides cut at 4 microns. Circle H&E for tech-only.

### Storage & Transportation

Refrigerate specimen. Do not freeze. Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

### CPT Code(s)\*

88374x1 automated or 88377x1 manual

### New York Approved

Yes

### Level of Service

Global, Technical

### Turnaround Time

3-5 days

## References

1. Swerdlow SH, et al. WHO classification of tumors of hematopoietic and lymphoid tissues (Revised 4th edition). IARC Press, Lyon 2017
2. Salaverria I, et al. A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. *Blood*. 2014;123:1187-1198.
3. Ferreiro JF et al. Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern. *Haematologica*. 2015;100:e275-e279.
4. Grygalewicz B, et al. The 11q-gain/loss aberration occurs recurrently in MYC-negative Burkitt-like lymphoma with 11q aberration, as well as MYC-positive Burkitt lymphoma and MYC-positive high-grade B-cell lymphoma, NOS. *Am J Clin Pathol*. 2018;149:17-28.

\*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

\*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way  
Fort Myers, FL 33912  
Phone: 239.768.0600/ Fax: 239.690.4237  
neogenomics.com  
© 2024 NeoGenomics Laboratories, Inc. All Rights Reserved.  
All other trademarks are the property of their respective owners  
Rev. 052024